Real-time Estimate
Cboe BZX
12:37:22 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
8.965
USD
|
+2.69%
|
|
+1.36%
|
+76.38%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
35.86
|
106
|
132.4
|
271.4
|
139.3
|
260
|
-
|
-
|
Enterprise Value (EV)
1 |
35.86
|
106
|
132.4
|
271.4
|
62.58
|
252.8
|
260
|
260
|
P/E ratio
|
-1.45
x
|
-4.26
x
|
-5.01
x
|
-7.77
x
|
-2.78
x
|
-5.89
x
|
-30.3
x
|
5.83
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
116
x
|
263
x
|
1,719
x
|
-
|
4.1
x
|
1.83
x
|
EV / Revenue
|
-
|
-
|
116
x
|
263
x
|
773
x
|
-
|
4.1
x
|
1.83
x
|
EV / EBITDA
|
-
|
-5.06
x
|
-5.42
x
|
-8.12
x
|
-1.22
x
|
-4.92
x
|
4.53
x
|
1.23
x
|
EV / FCF
|
-
|
-4.85
x
|
-6.31
x
|
32.8
x
|
-1.32
x
|
-4.49
x
|
-6.28
x
|
-76.9
x
|
FCF Yield
|
-
|
-20.6%
|
-15.9%
|
3.05%
|
-75.9%
|
-22.3%
|
-15.9%
|
-1.3%
|
Price to Book
|
-
|
2.23
x
|
1.81
x
|
-
|
3.72
x
|
-9.39
x
|
-7.22
x
|
-
|
Nbr of stocks (in thousands)
|
5,490
|
13,587
|
22,031
|
25,483
|
27,413
|
29,783
|
-
|
-
|
Reference price
2 |
6.531
|
7.800
|
6.010
|
10.65
|
5.080
|
8.730
|
8.730
|
8.730
|
Announcement Date
|
5/8/20
|
3/31/21
|
3/25/22
|
3/31/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
1.144
|
1.03
|
0.081
|
-
|
63.47
|
142.4
|
EBITDA
1 |
-
|
-20.96
|
-24.44
|
-33.4
|
-51.13
|
-51.4
|
57.4
|
211.3
|
EBIT
1 |
-22.07
|
-22.39
|
-24.96
|
-34.1
|
-51.92
|
-48.54
|
-8.219
|
49.32
|
Operating Margin
|
-
|
-
|
-2,182.17%
|
-3,311.07%
|
-64,098.77%
|
-
|
-12.95%
|
34.64%
|
Earnings before Tax (EBT)
1 |
-21.9
|
-22.22
|
-24.77
|
-33.02
|
-48.82
|
-47.23
|
-3.083
|
67.15
|
Net income
1 |
-21.9
|
-22.22
|
-24.77
|
-33.02
|
-48.82
|
-47.23
|
-6.974
|
55.52
|
Net margin
|
-
|
-
|
-2,165.56%
|
-3,205.53%
|
-60,269.14%
|
-
|
-10.99%
|
38.99%
|
EPS
2 |
-4.500
|
-1.830
|
-1.200
|
-1.370
|
-1.830
|
-1.483
|
-0.2878
|
1.498
|
Free Cash Flow
1 |
-
|
-21.87
|
-21
|
8.278
|
-47.49
|
-56.3
|
-41.43
|
-3.38
|
FCF margin
|
-
|
-
|
-1,835.58%
|
803.69%
|
-58,627.16%
|
-
|
-65.28%
|
-2.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/8/20
|
3/31/21
|
3/25/22
|
3/31/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.023
|
0.94
|
0.045
|
0.045
|
-
|
-
|
-
|
-
|
0.081
|
-
|
-
|
-
|
-
|
1.441
|
20.69
|
EBITDA
1 |
-7.911
|
-5.027
|
-7.67
|
-9.578
|
-11.13
|
-11.4
|
-15.43
|
-14.15
|
-10.14
|
-9.381
|
-11.4
|
-14.1
|
-16.4
|
-
|
-
|
EBIT
1 |
-8.048
|
-5.164
|
-7.85
|
-9.799
|
-11.29
|
-11.58
|
-15.64
|
-14.35
|
-10.34
|
-9.597
|
-10.95
|
-12.65
|
-14
|
-15.86
|
3.188
|
Operating Margin
|
-34,991.3%
|
-549.36%
|
-17,444.44%
|
-21,775.56%
|
-
|
-
|
-
|
-
|
-12,769.14%
|
-
|
-
|
-
|
-
|
-1,100.42%
|
15.41%
|
Earnings before Tax (EBT)
1 |
-8.01
|
-5.129
|
-7.767
|
-9.474
|
-10.65
|
-11.04
|
-15.18
|
-13.28
|
-9.324
|
-8.67
|
-12.57
|
-13.23
|
-12.8
|
-15.86
|
3.188
|
Net income
1 |
-8.01
|
-5.129
|
-7.767
|
-9.474
|
-10.65
|
-11.04
|
-15.18
|
-13.28
|
-9.324
|
-8.67
|
-12.57
|
-13.23
|
-12.8
|
-15.86
|
1.705
|
Net margin
|
-34,826.09%
|
-545.64%
|
-17,260%
|
-21,053.33%
|
-
|
-
|
-
|
-
|
-11,511.11%
|
-
|
-
|
-
|
-
|
-1,100.42%
|
8.24%
|
EPS
2 |
-0.3600
|
-0.2300
|
-0.3300
|
-0.3800
|
-0.4300
|
-0.4300
|
-0.5800
|
-0.4900
|
-0.3300
|
-0.3100
|
-0.4367
|
-0.4400
|
-0.4000
|
-0.4700
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/22
|
5/13/22
|
8/12/22
|
11/14/22
|
3/31/23
|
5/15/23
|
8/14/23
|
11/2/23
|
3/29/24
|
4/26/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
76.7
|
7.22
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-21.9
|
-21
|
8.28
|
-47.5
|
-56.3
|
-41.4
|
-3.38
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-94.9%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
3.500
|
3.320
|
-
|
1.370
|
-0.9300
|
-1.210
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-1.780
|
-1.540
|
-0.3800
|
-
|
Capex
|
-
|
0.25
|
0.13
|
0.37
|
0.15
|
-
|
0.68
|
1.85
|
Capex / Sales
|
-
|
-
|
11.63%
|
35.53%
|
188.89%
|
-
|
1.07%
|
1.3%
|
Announcement Date
|
5/8/20
|
3/31/21
|
3/25/22
|
3/31/23
|
3/29/24
|
-
|
-
|
-
|
Last Close Price
8.73
USD Average target price
25.47
USD Spread / Average Target +191.71% Consensus |
1st Jan change
|
Capi.
|
---|
| +71.85% | 260M | | +3.91% | 109B | | +10.87% | 105B | | +0.20% | 22.25B | | -13.14% | 22.09B | | -8.33% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|